rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IONS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Guggenheim cuts Ionis stock price target to $65 on revenue miss
      14h agoInvesting.comIONS
      Ionis at Jefferies Global Healthcare Conference: launch gains and hurdles
      17h agoInvesting.comIONSJEF
      Ionis, Sobi granted EU label expansion for Tryngolza
      Nov 17Seeking AlphaIONS
      Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start
      Nov 16Yahoo FinanceIONS
      Ionis at UBS Global Biopharma Conference 2026: launch pace in focus
      Nov 16Investing.comIONSUBS
      Arrowhead FY2026 Earnings Analysis: Pricey R&D Must Deliver As Market Turns On RNAi
      Nov 13Seeking AlphaIONS
      The Strategy Exited Ionis Pharmaceuticals (IONS) Following Sequential Phase 3 Clinical Setbacks
      Nov 13Yahoo FinanceIONS
      Ionis reports two-year data for hereditary angioedema drug
      Nov 12Investing.comIONS
      Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
      Nov 12Yahoo FinanceIONS
      Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings
      Nov 11Yahoo FinanceIONS
      IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
      Nov 10MorningstarIONS
      RBC cuts Ionis Pharmaceuticals stock price target on revenue miss
      Nov 10Investing.comIONS
      TD Cowen cuts Ionis Pharmaceuticals stock price target on Tryngolza miss
      Nov 10Investing.comIONS
      Wells Fargo cuts Ionis Pharmaceuticals price target on slower launch
      Nov 10Investing.comIONS
      Ionis Pharmaceuticals Inc (IONS) (Q3 2026) Earnings Call Highlights: DAWNZERA Momentum and ...
      Nov 10Yahoo FinanceIONS
      BofA cuts Ionis Pharmaceuticals stock price target on lower sales outlook
      Nov 10Investing.comIONS
      Ionis Stock In Focus After Revenue Beat And Reaffirmed 2026 Outlook
      Nov 10Yahoo FinanceIONS
      Ionis: 3 Key Takeaways for Long-Term Investors
      Nov 10Yahoo FinanceIONS
      Ionis Pharmaceuticals: Q3 Triggers The Latest Selloff On Tryngolza Disappointment (IONS)

      Ionis Pharmaceuticals, Inc. stock sank after earnings as 2026 sales guidance was cut and launch woes grew. Click for this IONS update.

      Nov 9Seeking AlphaIONS
      Raymond James cuts Ionis Pharmaceuticals price target on slow launch
      Nov 9Investing.comIONS
      Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday?
      Nov 9BenzingaIONS
      What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call
      Nov 9Yahoo FinanceIONS
      Ionis Q3 2026 slides: earnings beat can’t offset TRYNGOLZA concerns
      Nov 9Investing.comIONS
      Ionis Pharmaceuticals Reports 55% Rise in Q3 Revenue to $243 Million, Cuts TRYNGOLZA Sales Guidance
      Nov 9Yahoo FinanceIONS
      Ionis plummets as it cuts 2026 revenue guidance for Tryngolza

      Ionis stock sank after Tryngolza sales guidance was slashed despite a Q3 earnings beat.

      Nov 9Seeking AlphaIONS
      A failed trial for a heart drug casts shadow over rivals developing similar therapies

      The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.

      Nov 9MarketWatchIONS
      Ionis Stock Sinks as Revenue Forecast for Key Drug Slashed by 50%

      Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.

      Nov 9Barron'sIONS
      Earnings call transcript: Ionis beats Q3 2026 estimates but shares sink 28%
      Nov 9Investing.comIONS
      Ionis Is Poised To Slam Into A 19-Month Low. Here's Why.

      Premarket trading suggests Ionis Pharmaceuticals will open at its lowest point since May 2025.

      Nov 9Investor's Business DailyIONS
      Nvidia, AMD, CoreWeave, Ionis, DraftKings, and More Stocks That Explain Today’s Market
      Nov 9Barron'sAMDCRWVDKNGFSLRINTCIONSNVDATTDBRK.B
      Ionis Pharmaceuticals (IONS) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 9Yahoo FinanceIONS
      Why is Ionis Pharmaceuticals stock tumbling today?
      Nov 9Investing.comIONS
      Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
      Nov 9Yahoo FinanceIONS
      Ionis Pharmaceuticals: Q3 Earnings Snapshot
      Nov 9Yahoo FinanceIONS
      Ionis reports third quarter 2026 financial results and highlights progress on key programs
      Nov 9Yahoo FinanceIONS
      Ionis Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
      Nov 9Yahoo FinanceIONS
      Arrowhead reports lower pancreatitis rates, early cholesterol drug results (ARWR:NASDAQ)
      Nov 8Seeking AlphaIONS
      Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
      Nov 7Seeking AlphaIONSNVS
      Ionis Pharmaceuticals (IONS) Stock Still Looks Pricey Despite Pelacarsen Trial Failure
      Nov 7Yahoo FinanceIONS
      Ionis earnings on deck: Can Tryngolza justify blockbuster hype?
      Nov 3Investing.comIONS
      Ionis to hold third quarter 2026 financial results webcast
      Nov 2Yahoo FinanceIONS
      Ionis Pharmaceuticals stock hits 52-week low at 42.08 USD
      Nov 2Investing.comIONS
      Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
      Oct 28Yahoo FinanceIONS
      Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside (NASDAQ:IONS)
      Oct 25Seeking AlphaIONS
      Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
      Oct 23Yahoo FinanceIONS
      Ionis ranked #1 on Science’s Top Employers list
      Oct 22Yahoo FinanceIONS
      Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment
      Oct 22Yahoo FinanceIONS
      Ionis Pharmaceuticals stock price target maintained at $100 by H.C. Wainwright on HBV approval
      Oct 22Investing.comIONS
      Ionis upgraded at BMO on Tryngolza adoption for severe hypertriglyceridemia (IONS:NASDAQ)
      Oct 21Seeking AlphaIONS
      BMO upgrades Ionis Pharmaceuticals stock rating on sHTG opportunity
      Oct 21Investing.comIONS

      This is the newest page. Registered accounts read further back.